



Full Length Article

Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry



Jose Portillo ^{a,b}, Iris Violeta de la Rocha ^a, Llorenç Font ^c, Andrei Braester ^d, Olga Madridano ^e, José Antonio Díaz Peromingo ^f, Alessandro Apollonio ^g, Barbara Pagán ^h, José Bascuñana ⁱ, Manuel Monreal ^{j,*}, the RIETE Investigations ¹

^a Department of Internal Medicine, Hospital General Universitario de Ciudad Real, Spain

^b Facultad de Medicina de Ciudad Real, Universidad de Castilla La Mancha, Spain

^c Department of Haematology, Hospital de Tortosa Verge de la Cinta, Tarragona, Spain

^d Department of Haematology, Galilee Medical Center, Nahariya, "Azriel" Faculty of Medicine in Galilee, Bar-ilan University, Israel

^e Department of Internal Medicine, Hospital Infanta Sofía, Madrid, Spain

^f Department of Internal Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

^g Department of Angiology, Ospedale Belcolle di Viterbo, Viterbo, Lazio, Italy

^h Department of Internal Medicine, Hospital de Madrid Norte Sanchinarro, Madrid, Spain

ⁱ Department of Internal Medicine, Hospital Infanta Leonor, Madrid, Spain

^j Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Católica de Murcia, Spain

ARTICLE INFO

Article history:

Received 26 August 2015

Received in revised form 5 October 2015

Accepted 29 October 2015

Available online 30 October 2015

Keywords:

Venous thromboembolism

Glioblastoma

Anticoagulant therapy

Bleeding

Recurrences

ABSTRACT

Background: There is uncertainty about the optimal therapy of venous thromboembolism (VTE) in patients with glioblastoma multiforme (GBM).

Methods: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in patients with GBM, other cancers and in patients without cancer.

Results: As of September 2014, 53,546 patients have been recruited in RIETE. Of these, 72 (0.13%) had GBM and 11,811 (22%) had other cancers. Most patients in all 3 subgroups received initial therapy with low-molecular-weight heparin (LMWH), but those with GBM received slightly lower doses than those with other cancers or without cancer. Then, most patients with GBM continued on LMWH for long-term therapy, at similar doses than those in the other subgroups. During the course of anticoagulation (mean, 202 days), 3 patients with GBM presented VTE recurrences (10.9 per 100 patient-years; 95% CI: 2.76–29.5) and 4 suffered major bleeding (one intracranial) (14.5 bleeds per 100 patient-years; 95%CI: 4.60–34.9). Compared with patients with other cancers, those with GBM had a similar rate of VTE recurrences and major bleeds, but had a higher rate of extracranial hematoma ($p < 0.05$). Compared with VTE patients without cancer, those with GBM had a higher rate of PE recurrences ($p < 0.01$) and major bleeding ($p < 0.001$), particularly extracranial hematoma ($p < 0.001$).

Conclusions: Patients with GBM and VTE had a similar rate of VTE recurrences or major bleeds during the course of anticoagulant therapy than those with other cancers.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Patients with central venous system malignancies have a substantial risk for developing both thrombotic and bleeding disorders. The risk of venous thromboembolism (VTE) is substantially higher in these patients, both in the perioperative period and throughout their disease course. These patients harbor a latent hypercoagulability, which predisposes to VTE, as do postoperative immobility, hemiparesis, and other

factors. Using the UK Clinical Practice Research Database, the incidence rate of VTE was compared in 83,203 patients with cancer and in 577,207 age-matched control subjects without cancer. VTE events were found in 3352 (4.0%) patients with- and in 6353 (1.1%) without cancer [1]. The highest relative risk was found for pancreas, ovary or brain cancer. In another study using the Rochester epidemiological database, all cancer sites had an increased standardized morbidity ratio, ranging from 4.1 for head neck cancer to 47.3 for brain cancer [2]. Glioblastoma multiforme (GBM) is the most aggressive malignant primary brain tumor in adults. It is a highly vascularized tumor, and the advent of angiogenic inhibitors has been associated with an increased risk of VTE and bleeding [3–7]. The management of VTE in these patients is complex, given the significant morbidity and mortality associated with

* Corresponding author at: Servicio de Medicina Interna, Hospital Universitari Germans Trias i Pujol, 08916 Badalona (Barcelona), Spain.

E-mail address: mmonreal.germanstrias@gencat.cat (M. Monreal).

¹ A full list of RIETE investigators is given in the Appendix A.

intratumoral bleeding. The perceived risk of intracranial bleeding limits the use of anticoagulation for the management of VTE with many doctors favoring the use of inferior vena cava filter only for treatment [8,9].

The RIETE (Registro Informatizado Enfermedad TromboEmbólica) initiative is an ongoing, multicenter, international (Spain, Argentina, Belgium, Canada, Czech Republic, Ecuador, France, Greece, Israel, Italy, Latvia, Portugal, Republic of Macedonia, Switzerland, and Venezuela enrolled patients) observational registry of consecutive patients with symptomatic, objectively confirmed, acute VTE. It started in Spain in 2001, and some years later the database was translated into English aimed to expand the Registry to other countries, ultimately allowing physicians worldwide to use the database to select the most appropriate therapy for their patients. Data from this registry have been used to evaluate outcomes after VTE, such as the frequency of recurrent VTE, major bleeding and mortality, and risk factors for such outcomes [10–15]. The current study used the RIETE database to compare the rate of major bleeding and VTE recurrences during the course of anticoagulant therapy in patients with GBM versus those with other cancers and in patients without cancer.

2. Methods

Consecutive patients with symptomatic acute VTE confirmed by objective tests (contrast venography or ultrasonography for suspected deep vein thrombosis [DVT], pulmonary angiography, lung scintigraphy or helical computed tomography scan for suspected PE) were enrolled in RIETE. Patients were excluded if currently participating in a therapeutic clinical trial with a blinded therapy. All patients provided written or oral consent for participation in the registry, in accordance with local ethics committee requirements.

Participating physicians ensured that eligible patients were consecutively enrolled. Data were recorded on to a computer-based case report form at each participating hospital and submitted to a centralized coordinating center through a secure website. The study-coordinating center assigned patients with a unique identification number to maintain patient confidentiality and was responsible for all data management. Data quality was regularly monitored electronically, including checks to detect inconsistencies or errors, which were resolved by contacting the local coordinators. Data quality was also monitored by periodic visits to participating hospitals by contract research organizations that compared medical records with the submitted data.

2.1. Study design and outcomes

For this analysis, cancer patients with newly diagnosed cancer (less than 3 months earlier) or with cancer being treated by either surgery, chemotherapy, radiotherapy, hormonal, support therapy or combined treatments, were considered. Major outcomes were the rate of VTE recurrences and major bleeding. Bleeding complications were classified as 'major' if they were overt and required a transfusion of two units of blood or more, or were retroperitoneal, spinal or intracranial, or when they were fatal. Secondary outcomes were all-cause death, fatal PE and fatal bleeding. Fatal PE, in the absence of autopsy, was defined as any death appearing within the first 10 days after PE diagnosis (either the initial PE episode or recurrent PE), in the absence of any alternative cause of death. Fatal bleeding was defined as any death occurring within 10 days of a major bleeding episode, in the absence of an alternative cause of death. Most outcomes were classified as reported by the clinical centers. However, if staff at the coordinating center were uncertain how to classify a reported outcome, that event was reviewed by a central adjudicating committee (less than 10% of events).

2.2. Baseline variables

The following parameters were recorded when the qualifying episode of VTE was diagnosed: patient's gender, age, and body weight;

presence of coexisting conditions, concomitant medications and additional VTE risk factors including recent immobilization (defined as non-surgical patients confined to bed with bathroom privileges for ≥ 4 days in the 2-months prior to VTE diagnosis) and surgery (defined as an operation in the 2 months prior to VTE) were recorded. Moreover, recent (< 30 days prior to VTE) major bleeding, clinical characteristics of the malignancy (cancer site, staging, cancer duration since diagnosis), laboratory data on admission and treatment details (including drug, dose and duration of anticoagulant therapy) were also recorded.

2.3. Treatment and follow-up

Patients were managed according to the local clinical practice of each participating hospital i.e., there was no standardization of anticoagulation treatment. During each visit after onset of VTE, either in hospital or in the outpatient clinic after discharge, any signs or symptoms suggesting VTE recurrences or major bleeding during the course of anticoagulant therapy were noted. Clinically suspected recurrent VTE was investigated by repeated imaging as appropriate according to local physician practice.

2.4. Statistical analysis

Categorical variables were reported as percentages and compared using the chi-square test (two-sided) and Fisher's exact Test as appropriate. Odds ratios and corresponding 95% confidence intervals were calculated, and a p value < 0.05 was considered to be statistically significant. Continuous variables were compared with a Student t test. Incidence rates were calculated as cumulative incidence (events/100 patient-years). Statistical analyses were conducted using SPSS for Windows Release (version 20, SPSS Inc. Chicago, Illinois).

3. Results

As of September 2014, 53,546 patients with acute VTE have been recruited in RIETE. Of these, 72 (0.13%) had GBM and 11,811 (22%) had other cancers. Patients with GBM were significantly younger and less likely had chronic lung disease or anemia, but more likely had recent surgery (36% vs. 14%) or immobility (32% vs. 19%) than those with other cancers (Table 1). Moreover, patients with GBM had earlier occurrence of VTE after diagnosis of cancer, and were more likely receiving corticosteroids at VTE presentation (70% vs. 13%) but less likely were to be using antiplatelet drugs. The proportion of patients initially presenting with PE was similar in both subgroups. As to the treatment of cancer, patients with GBM more likely received radiotherapy (41% vs. 9.6%) than those with other cancers. Compared with patients without cancer, those with GBM were more likely men, less likely had chronic lung disease and more likely had recent surgery. They more likely were taking corticosteroids but less likely received antiplatelets (Table 1).

The duration of anticoagulant therapy was significantly shorter in patients with GBM (median: 96 days) than in the other two subgroups (median: 133 and 185 days, respectively), as shown in Table 2. Most patients in all 3 subgroups received initial therapy with LMWH, but those with GBM received slightly lower doses (164 ± 48 IU/kg/day) than those with other cancers (175 ± 43 IU/kg/day) or without cancer (179 ± 39 IU/kg/day). Then, the majority of patients with GBM continued on LMWH for long-term therapy, at similar doses than those in patients with other cancers or without cancer.

During the course of anticoagulation (mean, 202 days), 3 patients with GBM presented VTE recurrences (10.9 per 100 patient-years; 95% CI: 2.76–29.5), 4 suffered major bleeding (one intracranial) (14.5 bleeds per 100 patient-years; 95% CI: 4.60–34.9) and 34 died (122; 95% CI: 85.8–168), as shown in Table 3. Compared with patients with other cancers, those with GBM had a similar rate of VTE recurrences and major bleeds, but had a higher rate of extracranial hematoma ($p < 0.01$) and

Download English Version:

<https://daneshyari.com/en/article/6001025>

Download Persian Version:

<https://daneshyari.com/article/6001025>

[Daneshyari.com](https://daneshyari.com)